Zedira is a privately held clinical stage biotech company based in Darmstadt, Germany.

The Company focuses on disorders linked to the enzyme family of transglutaminases.

Zedira’s business model is focused on the development of small molecule drug candidates for early licensing.
Zedira’s drug candidate for celiac disease therapy, tissue transglutaminase (TG2) blocker ZED1227 is currently tested in phase Ib clinical trials.
ZED1227 is licensed to Dr. Falk Pharma for Europe. Dr. Falk Pharma took over responsibility for preclinical and clinical development as well as for approval and marketing of the drug.

Zedira now taps the potential of ZED1227 to address additional indications where dysregulated tissue transglutaminase (TG2) activity is targeted, especially fibrotic disorders (e.g. diabetic nephropathy).

Current development work focuses on safe anticoagulation (thromboprophylaxis) by coagulation FXIIIa blockers (F13a, plasma transglutaminase). This novel approach has the potential of a significant reduction in the life-threatening tendency to bleeding as provoked by current drugs.

In a rabbit animal model, Zedira already showed the proof-of-principle of “safe” anticoagulation therapy by inhibition of Factor XIIIa.

The Company’s management is open to considering investment by private individuals and institutions.
Please do not hesitate to contact us if you are interested in an attractive opportunity.

Zedira’s managing partners, Dr. Martin Hils and Dr. Ralf Pasternack, will be pleased to be at your disposal:

Phone:      +49 6151 3251-00 or
E-mail:      contact@zedira.com


Meet Dr. Pasternack at Bio-Europe in Cologne!

Meet Dr Pasternack at Bio-Europe 2016
  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • Transglutaminases in Medicine

      03.08.2017 - 05.08.2017
      Debrecen, Hungary

    • 15th Congress on Amino Acids, Peptides and Proteins

      07.08.2017 - 11.08.2017
      Vienna, Austria

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland